Clinical trials: Solid Malignant Tumor
Unspecified Adult Solid Tumor, Protocol Specific
Dimethylxanthenone Acetic Acid in Treating Patients With Solid Tumors
RATIONALE: Dimethylxanthenone acetic acid may stop the growth of cancer cells by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of dimethylxanthenone acetic acid in treating patients with…
- Trial name
- NCT00003697
- Testing
- vadimezan
- Where
- United Kingdom
- Volunteers
- 3 people
- Sponsor
- University of Glasgow
Advanced Solid Tumor Cancer
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GH2616 in Subjects With Advanced Solid Tumor.
GH2616 is a potent and selective inhibitor targeting KIF18A, exhibiting distinct and superior anticancer properties compared to other cell cycle and anti-mitotic drug targets, with significant inhibitory effects on TP53 mutant…
- Trial name
- GH2616C102 (NCT07260513)
- Testing
- GH2616 Tablets for oral administration at specified doses on scheduled days.
- Where
- 2 sites in China
- Volunteers
- 126 people
- Sponsor
- Suzhou Genhouse Bio Co., Ltd.
Unspecified Childhood Solid Tumor, Protocol Specific
Irinotecan in Treating Children With Refractory or Advanced Solid Tumors Who Are Receiving Anticonvulsants
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of irinotecan in treating children with refractory or…
- Trial name
- NCT00008424
- Testing
- irinotecan hydrochloride
- Where
- 51 sites in United States, Australia and 1 more
- Volunteers
- 7 people
- Sponsor
- Children's Oncology Group
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Voices: Messages of Wisdom and Hope in the Face of Illness
This study may help doctors determine where patients and caregivers may need more support and identify ways to maintain patient and caregiver dignity while undergoing treatment.
- Trial name
- NCT07381179
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Cancer
A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors
The purpose of this study is to evaluate the safety and dose regimen of CNTO 888 when administered to patients with solid tumors in combination with 4 standard of care chemotherapy regimens.
- Trial name
- NCT01204996
- Testing
- CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection, CNTO888 + gemcitabine, CNTO888 + Paclitaxel and carboplatin
- Where
- 5 sites in United States, Spain
- Volunteers
- 53 people
- Sponsor
- Centocor, Inc.
RAS Mutation, Advanced Solid Tumor
A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations
The purpose of this study is to test if the BG-85738 is safe and if it works in patients with advanced solid tumors with RAS mutations when it is given on its own and in combination.
- Conditions
- RAS Mutation, Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT07746141
- Testing
- BG-85738, Tislelizumab, Cetuximab
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 100 people
- Sponsor
- BeOne Medicines
Colorectal Cancer, Liver Metastases
COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases
The primary objective of this phase IIb/III, prospective, randomized clinical trial is to compare the efficacy of irreversible electroporation (IRE) with stereotactic body radiotherapy (SBRT) in patients with perivascular or…
- Conditions
- Colorectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer, Unresectable Solid Tumor
- Trial name
- COLDFIRE-III (NCT06185556)
- Testing
- Irreversible electroporation, Stereotactic body radiotherapy
- Where
- Netherlands
- Volunteers
- 78 people
- Sponsor
- Amsterdam UMC, location VUmc
Neoplasm
Study of TRC102 in Combination With Pemetrexed in Cancer Patients
This study is being performed to evaluate the safety and tolerability of TRC102 in combination with Alimta. In addition to safety, this study will also evaluate pharmacokinetics and tumor response.
- Trial name
- NCT00692159
- Testing
- TRC102 + pemetrexed
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Advanced Solid Tumor
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
This is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors.
- Trial name
- NCT07749586
- Testing
- ARV-6723, Pembrolizumab, SOC
- Where
- 4 sites in United States
- Volunteers
- 499 people
- Sponsor
- Arvinas Inc.
Advanced Solid Tumor
ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
- Trial name
- NCT06332170
- Testing
- HS-20093, Adebrelimab, Cisplatin/ Carboplatin
- Where
- China
- Volunteers
- 610 people
- Sponsor
- Hansoh BioMedical R&D Company
Recurrent Brain Metastases, Progressive Brain Metastases
Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary
Cancer that has spread to the brain, or brain metastasis, is difficult to treat. Meclofenamate is a drug which has been shown to reduce brain metastasis growth in the laboratory.
- Trial name
- NCT02429570
- Testing
- Meclofenamate
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Solid Tumor Cancer
Bioequivalence Study of Trifluridine and Tipiracil Hydrochloride Tablets on Fasting and Fed in Humans
The test formulation of Trifluridine and Tipiracil Tablets (20 mg) is bioequivalent to the reference formulation (Lonsurf®) in Chinese patients with solid tumors under fed and fasting conditions.
- Trial name
- NCT07492173
- Testing
- Trifluridine and Tipiracil Tablets, Lonsurf®
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Metastatic Solid Tumor, Brain Metastases
A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
To learn if the study drugs, tucatinib and adotrastuzumab emtansine (T-DM1), can help to control solid tumors that have spread to the brain.
- Trial name
- NCT05673928
- Testing
- Trastuzumab emtansine, Tucatinib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Ototoxicity, Unspecified Adult Solid Tumor
Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin
RATIONALE: Alpha-lipoic acid may prevent or lessen hearing loss caused by cisplatin. PURPOSE: This randomized clinical trial is studying the effectiveness of alpha-lipoic acid in preventing hearing loss in cancer patients…
- Trial name
- NCT00477607
- Testing
- alpha-lipoic acid, Audiology, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- US Department of Veterans Affairs
Solid Tumor, Adult
Cannabis Use in Cancer Patients
The goal of this study is to determine the feasibility of a human observational study of orally administered cannabis use among cancer patients.
- Trial name
- NCT03617692
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- University of Colorado, Denver
Advanced Cancer, Advanced Solid Tumor
Oral Administration of STC-15 in Subjects With Advanced Malignancies
This Phase 1, multi-center, open-label, first-in-human study evaluates multiple ascending daily oral doses of STC-15 in Q3W treatment cycles in a 3+3 cohort design with dose levels determined by a modified Fibonacci algorithm.
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Cancer
- Trial name
- NCT05584111
- Testing
- STC-15
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- STORM Therapeutics LTD
Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with…
- Conditions
- Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
- Trial name
- NCT06162221
- Testing
- RMC-6291, RMC-6236, Pembrolizumab
- Where
- 98 sites in United States, Australia and 11 more
- Volunteers
- 616 people
- Sponsor
- Revolution Medicines, Inc.
Solid Tumors, Metastatic Disease
CPCT-05 Biopsy Protocol Patient Selection
Our knowledge on the genetic mutations in cancer is rapidly expanding and we are increasingly testing drugs in mainly metastatic cancer patient populations with rare mutations.
- Trial name
- NCT01904916
- Testing
- Histological biopsy procedure
- Where
- 3 sites in Netherlands
- Volunteers
- 195 people
- Sponsor
- P.O. Witteveen
Lymphoma, Metastatic Malignant Solid Neoplasm
Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma
This phase Ib trial studies the side effects and best dose of copanlisib and nivolumab and side effects of copanlisib given together with nivolumab and ipilimumab in treating patients with solid tumors that may have spread from…
- Conditions
- Lymphoma, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Trial name
- NCT03502733
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignancies, Metastatic Cancer
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
- Trial name
- NCT03277352
- Testing
- INCAGN01876, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Biosciences International Sàrl
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.